1
Clinical Trials associated with Quadrivalent Influenza mRNA Vaccine MRT5421(Sanofi Pasteur) / Active, not recruitingPhase 1/2 A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
100 Clinical Results associated with Quadrivalent Influenza mRNA Vaccine MRT5421(Sanofi Pasteur)
100 Translational Medicine associated with Quadrivalent Influenza mRNA Vaccine MRT5421(Sanofi Pasteur)
100 Patents (Medical) associated with Quadrivalent Influenza mRNA Vaccine MRT5421(Sanofi Pasteur)
100 Deals associated with Quadrivalent Influenza mRNA Vaccine MRT5421(Sanofi Pasteur)